Neurorehabilitation devices market seen reaching $6.98 billion by 2035

Market Research Future projects the global neurorehabilitation devices market will grow from $2.17 billion in 2026 to $6.98 billion by 2035, driven by rising neurological disease cases, faster regulatory clearances and AI-enabled rehabilitation tools. The forecast points to strong growth in brain-computer interfaces, robotic therapy systems and home-based care across North America, Europe and Asia-Pacific.

Why it matters: - The neurorehabilitation devices market is expanding fast as hospitals, clinics and home-care providers respond to rising demand for stroke recovery, dementia care and other neurological treatment. - Market Research Future projects the market will rise from $2.17 billion in 2026 to $6.98 billion by 2035, a 14.8% compound annual growth rate. - The forecast matters because the market is being shaped by regulatory approvals, reimbursement changes and wider use of AI-assisted therapy.

What happened: - Market Research Future released a forecast on June 10, 2026 for the global neurorehabilitation devices market. - The report estimates the market base at $1.89 billion in 2025. - The forecast covers products used in stroke rehab, Parkinson’s disease care, multiple sclerosis, spinal cord injury, cerebral palsy, cognitive rehabilitation and home-based therapy. - The report also includes regional and competitive outlooks through 2035. - The source release links to a free sample request and the full report.

The details: - More than 1 billion people worldwide live with neurological disorders, and stroke accounts for 6.5 million deaths a year, according to the release. - The World Alzheimer Report 2021 counted more than 55 million dementia cases globally, with that figure expected to reach 78 million by 2030. - By 2030, the global population aged 60 and older is expected to reach 1.4 billion, adding pressure on rehabilitation services. - The FDA’s 2021 De Novo clearance of the IpsiHand System opened a pathway for brain-computer interface therapy devices. - The release says at least seven more neural interface devices are now in the FDA review queue. - CMS introduced new reimbursement codes for brain-computer interface therapy sessions effective January 2025. - Robotic exoskeletons and end-effector systems showed 30% to 40% better upper-limb motor outcomes than conventional therapy in a 2023 Cochrane review, according to the report. - Early clinical trials show AI-optimized protocols can improve motor recovery timelines by 25% versus standardized programs. - Neuro-robotic devices held about 35% of the market in 2025. - Brain-computer interfaces are projected to be the fastest-growing product segment at 18.2% CAGR from 2026 to 2035. - Non-invasive stimulators generated $420 million in revenue in 2025. - Wearable devices are projected to grow at 16.3% CAGR from 2026 to 2035. - Brain stroke remained the dominant application in the market. - Parkinson’s disease is a growing application area, supported by deep brain stimulation and neuromodulation adoption. - Hospitals and clinics accounted for about 52% of end-user share in 2025. - Cognitive care centers are projected to be the fastest-growing end-user segment at 16.1% CAGR. - Home care held about 11% share in 2025 and is expected to expand as wearable and gamified devices move into unsupervised use.

Between the lines: - The market forecast reflects a shift from isolated rehabilitation devices toward connected, software-driven therapy platforms. - Funding from government programs is helping build the infrastructure needed to support adoption. - The U.S. BRAIN Initiative has directed more than $3.2 billion into neuroscience research since inception, including $690 million in fiscal 2024 from NIH. - The EU’s Horizon program supports neural plasticity therapy device research, and the European Research Council plans more than $4.5 billion in neural plasticity research through 2032. - China’s State Council rehabilitation services plan aims to establish dedicated neurorehabilitation units in every prefecture-level city by 2030. - India’s Ayushman Bharat program is also adding rehabilitation infrastructure. - The report says the competitive field is moderately fragmented, with the top five players holding 42% to 48% of revenue. - Hocoma, Ekso Bionics, Bionik Laboratories, Medtronic, Abbott Laboratories, MindMaze, Neurolutions, BrainCo and Nexstim are among the named companies in the market. - The release points to a broader commercial pivot toward subscription services, remote monitoring and data analytics instead of one-time device sales.

What’s next: - Closed-loop AI therapy systems are expected to become standard by 2030, according to the report. - Commercial deployment of closed-loop brain-computer interface systems is expected by 2028. - The report says about 40% of stroke rehabilitation equipment revenue could come from software updates, remote monitoring and analytics by 2030. - Simplified, lower-cost systems for community use could broaden access in low-income markets by 2035. - Telerehabilitation is expected to expand access in rural and underserved regions where many stroke survivors do not receive specialized care in the first 90 days.

The bottom line: - Neurorehabilitation is moving from niche clinical hardware to a larger, faster-growing market built on regulation, reimbursement and digital therapy.